No increase in adverse events with liposomal bupivacaine vs placebo in elective lumbar spine surgery
Can Liposomal Bupivacaine Be Safely Utilized in Elective Spine Surgery?Global Spine J. 2019 Apr; 9(2): 133–137.
Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here
59 patients with degenerative spondylosis scheduled for elective open posterior lumbar decompression and instrumented fusion were randomized to receive a pre-wound closure injection of liposomal bupivacaine (266mg) or placebo for the treatment of post-operative pain. The primary outcome of interest was the incidence of adverse events. The secondary outcome of interest was the length of hospital st...
Continuing Medical Education Credits
You could be earning 0.5 CME credits for each report you read.LEARN MORE